CHARLOTTE, N.C., Sept. 24, 2007 (PRIME NEWSWIRE) -- Following a successful meeting with the FDA, Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced its planned clinical protocol for its Phase III trials of Droxidopa in Neurogenic Orthostatic Hypotension (NOH) and intends to initiate patient dosing during the fourth quarter of 2007.
